This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Increasingly, clinical trials are using patient-reported outcomes (PROs) as primary outcome measures, so as to improve the assessment of the overall effect of the intervention on the patient as a whole, rather than the more restricted assessment of the intervention on the condition itself. Consistent and reliable measurement of the effects of treatment for the patient is likewise becoming a larger part of clinical practice and reimbursement considerations. This is especially important for treatments that focus on reducing symptoms or improving function, rather than offering cure for a given condition. Measurement of the disease or treatment effect in a patient-centered way is especially critical in patients with neurologic conditions, since brain diseases, more so than other conditions, …
AAN Members: Sign in with your AAN member credentials (e-mail or 6-digit Member ID number)
Non-AAN Member subscribers: Sign in with subscriber credentials
Log in using your username and password
Purchase access
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.